Tech Company Financing Transactions
Exicure Funding Round
Exicure closed a $18 million Series C financing round on 2/6/2015. Investors included private investors.
Transaction Overview
Company Name
Announced On
2/6/2015
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series C
Investors
Proceeds Purpose
We anticipate that the completion of the Series C financing will be instrumental in the clinical testing of our lead programs in psoriasis and bladder cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8045 Lamon Ave. 410
Skokie, IL 60077
USA
Skokie, IL 60077
USA
Phone
Website
Email Address
Not Recorded
Overview
AuraSense Therapeutics is a development-stage biotechnology company founded to pursue the unique commercial potential of Spherical Nucleic Acid (SNA) constructs. These novel constructs possess unparalleled biocompatibility and versatility as therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Giljohann
Chief Financial Officer
David Snyder
Chief Operating Officer
Matthias Schroff
Browse more venture capital transactions:
Prev: 2/6/2015: Sight Machine venture capital transaction
Next: 2/6/2015: Inocucor venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs